Kaushal Chaudhari, MD
Family Medicine · Fort Oglethorpe, GANPI 1750680104
Payments from drug & device makers
Across 158 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$409
- Sanofi-aventis U.S. LLC$361
- Boehringer Ingelheim$198
- Novo Nordisk$189
- Abbott$186
- Amgen$132
- plus $968 from 23 others
What the payments were for
- Food & beverage$2,431100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $409 |
| Sanofi-aventis U.S. LLC | 22 | $361 |
| Boehringer Ingelheim | 12 | $198 |
| Novo Nordisk | 14 | $189 |
| Abbott | 11 | $186 |
| Amgen | 10 | $132 |
| Amarin Pharma, Inc. | 6 | $120 |
| GSK | 7 | $98 |
| Pfizer | 7 | $98 |
| Supernus Pharmaceuticals, Inc. | 7 | $95 |
| Johnson & Johnson | 5 | $86 |
| AstraZeneca | 5 | $71 |
| Bayer | 3 | $61 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Boston Scientific | 2 | $32 |
| Genentech USA, Inc. | 1 | $25 |
| Merck | 2 | $24 |
| Novartis | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Gilead | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,442 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 526 | $720,404 |
| OzempicSemaglutide | 210 | $294,169 |
| EliquisApixaban | 308 | $266,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 185 | $163,864 |
| TrulicityDulaglutide | 121 | $153,513 |
| JardianceEmpagliflozin | 116 | $134,152 |
| JanuviaSitagliptin Phosphate | 102 | $113,067 |
| XareltoRivaroxaban | 109 | $109,759 |
| EntrestoSacubitril/Valsartan | 94 | $104,827 |
| Tresiba Flextouch U-200Insulin Degludec | 101 | $98,457 |
| XifaxanRifaximin | 26 | $85,454 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $66,058 |
| ProliaDenosumab | 37 | $63,335 |
| FarxigaDapagliflozin Propanediol | 87 | $63,143 |
| LinzessLinaclotide | 62 | $52,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $12 | $873,918647 claims |
| PfizerEliquis, Nurtec Odt | $98 | $294,901332 claims |
| Novo NordiskOzempic | $189 | $294,169210 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $98 | $203,044272 claims |
| Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat | $198 | $185,141175 claims |
| MerckJanuvia | $24 | $113,067102 claims |
| Johnson & JohnsonXarelto | $86 | $109,759109 claims |
| NovartisEntresto | $21 | $104,82794 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $71 | $95,338155 claims |
| AbbVieLinzess, Ubrelvy, Qulipta | $409 | $85,52184 claims |
| AmgenProlia | $132 | $63,33537 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $35,82444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Fort Oglethorpe
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.